Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2025-12-08 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于信超妥、复立安、恩那罗等药品纳入国家医保目录的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the inclusion of certain drugs into the National Medical Insurance Directory for 2025. It details the drugs involved, their categories, agreement validity periods, and clinical information. The document is a formal announcement about regulatory and reimbursement status changes for the company's products, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document length is 2197 characters, which is relatively short and consistent with an announcement. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-12-08 Chinese
关于SAL0140获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of a clinical trial for a new drug (SAL0140) by the National Medical Products Administration. It contains no financial data, no financial statements, and no detailed report content. The document is short (949 characters) and serves as a notification about regulatory approval and future clinical trial plans. It does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not a management or board change announcement, nor a voting result or capital change. It is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2025-12-08 Chinese
关于SAL0140获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (934 characters) from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the receipt of a clinical trial approval notice for a drug (SAL0140). It includes no financial data, no detailed report content, and is primarily an official notification of a regulatory approval event. It does not contain financial statements, management discussion, or detailed report data. The document is an announcement of a regulatory event related to clinical trial approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories.
2025-12-03 Chinese
关于SAL0139获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (753 characters) from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the receipt of a clinical trial approval notice for a drug candidate SAL0139. It includes a guarantee of truthful disclosure and references prior announcements. There are no financial statements, detailed financial data, or management discussion. The document is an official announcement about regulatory approval related to clinical trials, not a financial report or detailed management report. It is not a report publication announcement since it contains substantive information about the clinical trial approval. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-11-21 Chinese
关于参加2025年度深圳辖区上市公司投资者网上集体接待日活动的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the company's participation in an online investor collective reception day event organized by regulatory and investor service bodies. It mentions the date and time of the event and that company management will interact with investors on topics such as company performance, governance, strategy, and sustainability. The document is short (580 characters) and serves as a notice of an upcoming investor event rather than a report or detailed financial disclosure. It does not contain financial statements, audit information, or voting results. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation for investors focusing on company information and interaction.
2025-11-14 Chinese
关于股东减持股份的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding a shareholder's plan to reduce their shareholding in the company. It details the shareholder's identity, the number of shares to be reduced, the reasons for reduction, and compliance with regulatory requirements. There are no financial statements, earnings data, or management discussions. The document is an announcement about a planned transaction in the company's shares by a shareholder, not a report or detailed financial filing. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2025-11-10 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.